baber/WOPTO huggingface dataset:
Patent NZ-528000-A (NZ)
Title: A construct comprising in operable linkage a polynucleotide that encodes a polypeptide with a half-life of less than three hours
Inventor: DALY JOHN
IPC: A01K67/027
Filed: 2002-03-08
Abstract: Expression vectors and their use in gene expression or gene regulation assays are described. More particularly described, are expression vectors and/or reporter vectors providing kinetics of protein expression with temporal correlation to promoter activity. Further described are expression vectors comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to the transcribable polynucleotide. The vectors can be used for identifying and analysing cis- and trans-acting regulatory sequences/factors as well as vectors and genetically modified cell lines or non-human organisms that are particularly useful for drug screening and drug discovery.
Patent NZ-528039-A (NZ)
Title: Method for purifying 20(S)-camptothecin
Inventor: SOBOTTA RAINER
IPC: C07D491/04
Filed: 2002-02-09
Abstract: The process for purifying 20(S)-camptothecine is described to comprise the following steps: (a) combining an aqueous base and a starting material containing 20(s)-camptothecine, thereby converting the lactone ring of the 20(S)-camptothecine into a carboxylate salt; (b) hydrogenating the resulting mixture in the presence of a transition metal catalyst; (c) acidifying the aqueous phase, thereby forming camptothecine crystals; (d) adding at least one polar aprotic solvent; and (e) separating off the camptothecine crystals. The starting material in step (a) is described to consist substantially of a mixture of the compounds of formula (I) wherein R1 denotes ethyl or vinyl; and be a natural plant product. Also disclosed is the process for preparing 20(S)-camptothecine of formula (I) wherein R1 denotes ethyl from a 20-vinyl-camptothecine of formula (I) wherein R1 denotes vinyl. This involves combining an aqueous base and the starting material containing 20-vinyl-camptothecine, to form a compound of formula (II). R1 denotes vinyl, and Met denotes a metal. Following this step, (b) to (e) described above are carried out.
Patent NZ-528834-A (NZ)
Title: Stable herbal dentifrice
Inventor: HEALY MARISSA
IPC: A61K8/55
Filed: 2002-04-19
Abstract: Disclosed is an oral health care formulation comprising: from about 60 to 70 wt. % of sodium bicarbonate; from about 0.5 to 5 wt. % of a blend of natural ingredients comprising echinacea, myrrh, chamomile, rhatany and sage; from about 0.5 to 5 wt. % of a flavoring oil; and a stabilising combination of from 0.3 to 3 wt. % of a xanthan gum binder, from 0.5 to 5 wt. % of at least one betaine surfactant and from 5 to 10 wt. % of at least one humectant consisting of glycerin or glycerin and sorbitol. The formulationas disclosed is stable to degradation and resistant to syneresis, and may further comprise a fluoride source.
Patent NZ-529836-A (NZ)
Title: Film fracture feature for peelable multilayer package lid
Inventor: BARMORE CHARLES RICE
IPC: B65D77/20
Filed: 2003-11-28
Abstract: A package for storing and shipping food products incorporates a multilayer film lid that includes a gas-impermeable exterior layer and a gas-permeable interior layer. The multilayer film lid is heat sealed to a flange of a tray upon which the food product is supported. The gas-impermeable layer may be delaminated from the gas-permeable layer when it is desired to expose the food to atmospheric gases. Separation of the gas-impermeable layer from the gas-permeable layer is facilitated by a film fracture feature included in the heat seal pattern adjacent a pull tab of the lid. The film fracture feature concentrates the separation forces exerted on the tab in a small area so that the gas-permeable layer of the lid readily breaks at the film fracture feature.
Patent NZ-530974-A (NZ)
Title: Handle assembly for tool
Inventor: WALKER ANDREW
IPC: F16F15/023
Filed: 2004-02-05
Abstract: A handle assembly for a power tool comprises a housing defining a handle (4) and a housing for a motor for actuating an output member of the tool, such as a drill bit or jigsaw blade. The handle assembly comprises at least one flexible sheet (8) adapted to be mounted to a surface of the handle of the power tool and having a series of protrusions (10) adapted to be engaged by a hand of a user of the tool. The protrusions retain one or more blister packs containing at least one vibration damping gel material between the flexible sheet and the surface of the handle.
Patent NZ-531768-A (NZ)
Title: Lean NOx trap/conversion catalyst including cobalt and at least one alkali metal or alkaline earth metal
Inventor: KOO KWANGMO
IPC: B01D53/94
Filed: 2002-09-17
Abstract: A process and composition for converting nitrogen oxides present in exhaust gases produced by an internal combustion engine, utilizing cobalt and at least one alkali metal or alkaline earth metal as a component of an adsorbent. The process involves contacting the exhaust gas with an adsorbent which adsorbs the nitrogen oxides in lean-burn conditions and recurrently reducing the oxygen concentration of the exhaust gas. During such periods of reduced oxygen concentration, the nitrogen oxides are then desorbed and reduced to nitrogen, thereby reducing the concentration of the nitrogen oxides in the exhaust gas. The composition of the adsorbent comprises an oxide support and at least two components loaded on the support and containing cobalt and at least one alkali metal or alkaline earth metal. The composition demonstrates improved activity at higher temperatures and improved thermal stability.
Patent NZ-533439-A (NZ)
Title: Methods for the treatment of peripheral neural and vascular ailments using flavonoid compositions
Inventor: ROSENBLOOM RICHARD A
IPC: A61K31/355
Filed: 2002-11-06
Abstract: Disclosed herein is a composition for the treatment of small fiber neuropathy and diabetic neuropathy consisting of a mixture formulated from a flavonoid having antioxidant properties in a therapeutically effective amount for the treatment of small fiber neuropathy or diabetic neuropathy; and a therapeutically effective amount for the treatment of small fiber neuropathy or diabetic neuropathy of a component selected from vitamin D3 1,25-dihydroxyvitamin D3, 1(S),3(R)- dihydroxy-20(R)-(1-ethoxy-5-ethyl-5-hydroxy-2-heptyn-1-yl)-9,10-seco-pregna- 5(Z),7(E),10(19)-triene, pharmaceutically acceptable salts thereof, and mixtures thereof; and an acceptable carrier.
Patent NZ-534305-A (NZ)
Title: Furanone derivatives
Inventor: WANG BING
IPC: C07D403/00
Filed: 2003-01-30
Abstract: Disclosed are compounds of formula I, R1 is -C(O)OR', -C(O)NR'R", -CH2OR"', cyano, optionally substituted heterocyclyl, heterocyclyl-alkyl, heteroaryl, heteroaralkyl, R2 is optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, nucleoside, amino acid, or di-, tri or tetra-peptide, R3 optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralykl, nucleoside, amino acid, or di-, tri- or tetra-peptide, R4 is H, alkyl, alkylcarbonyl, (poly)alkoxalkylene, or dialkoxyphosporyloxy, X is lower alkylene, -N(R')-, -S-, -S(O)-, -S(O)2-, or taken together with R2 is -P(O)(OR')2, Y is -N(R')-, -S-, -S(O)2-, or taken together with R3 is -P(O)(OR')2, or X-R2 taken together with Y-R3 forms an optionally substituted aliphatic or aromatic ring. The compounds are used in the manufacture of medicaments for the treatment of stroke, myocardial infarction and chronic heart failure, as well as oxidative stress-related conditions.
Patent NZ-535702-A (NZ)
Title: Method to inhibit cell growth using oligonucleotides
Inventor: ELLER MARK S
IPC: A61K41/00
Filed: 2003-04-11
Abstract: The use of one or more oligonucleotides which share at least between 55% and 99% nucleotide sequence identity with (TTAGGG)n in the manufacture of a medicament for treating a hyperproliferative disorder in a mammal, wherein n is any number from 1 to 3.
Patent NZ-537954-A (NZ)
Title: Plasma spheroidized zirconia ceramic powder
Inventor: WALLAR HOWARD
IPC: C23C4/10
Filed: 2003-08-04
Abstract: Disclosed are zirconia thermal spray powders suitable for application of a thermal barrier coating on a substrate that can be obtained by plasma spraying a chemically uniform homogeneous zirconia stabilized in the tetragonal form using a stabilizing oxide such as yttria to obtain a powder comprising substantially spherical hollow zircon a particles with sizes less than about 200 micrometers. Also disclosed is a process for the production of a chemically uniform thermal spray powder which comprises the steps of; (a) electrofusing zirconia with up to 60% by weight of an oxide (such as yttria, rare earth metal oxide, calcium oxide and magnesium oxide) effective to stabilize the zirconia in the tetragonal phase; (b) quenching the electrofused stabilized zirconia to obtain particulate stabilized zirconia with at least 96% of the zirconia in the tetragonal phase; (c) heat treating the stabilized zirconia to form substantially spherical hollow particles of stabilized zirconia with particle sizes of 200 micrometers or less.
Patent NZ-538014-A (NZ)
Title: Modular moulding part, for constructing a block panel, with stepped edges for overlapping engagement with adjacent moulding part
Inventor: LOFTUS ROY
IPC: E04B5/46
Filed: 2002-02-13
Abstract: A modular moulding part is disclosed, for constructing a block panel with flanges having stepped edges for engagement with an adjacent moulding part. (62) Divided out of 528181
Patent NZ-538812-A (NZ)
Title: Immunostimulatory compositions and methods of stimulating an immune response
Inventor: KEDL ROSS M
IPC: A61K39/395
Filed: 2003-08-14
Abstract: Disclosed is an immunostimulatory composition comprising an immune response modifier portion paired with an antigenic portion so that independent diffusion of the immune response modifier portion with respect to the antigenic portion is limited wherein the immune response modifier portion is a compound of formula (I).
Patent NZ-541595-A (NZ)
Title: Methods and compositions for the treatment of gastrointestinal disorders
Inventor: CURRIE MARK G
IPC: C07K7/06
Filed: 2004-01-28
Abstract: Disclosed are compositions for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides that activate the guanylate cyclase C (GC-C) receptor.
Patent NZ-545162-A (NZ)
Title: Bearing structure
Inventor: WOBBEN ALOYS
IPC: F03D1/06
Filed: 2004-08-05
Abstract: The load spar for a wing or wind-turbine blade is constructed of a composite of fibre bundles 20 in hardened epoxy resin 22. To assist in the formation of the spar, reduce the amount of resin needed at the wet lay-up stage, and prevent the formation of undulations as the resin cures, prefabricated stiff composite fibre reinforced elements 24 are laid-up with the fibres 20 at the wet lay-up stage. The composite elements might also be of the same fibres laid-up in the same resin.
Patent NZ-546417-A (NZ)
Title: Ceratamines A and B, and analogues, syntheses and pharmaceutical compositions thereof
Inventor: ANDERSEN RAYMOND J
IPC: A61K31/55
Filed: 2004-09-15
Abstract: Disclosed is a substantially purified or isolated compound or salt thereof, having the structure shown wherein: R1, R2, and R3 are independently selected from H, NH2, NHR, NR2, SH, SR, SiR3, OH, OR, F, CI, Br, I, and R; W is selected from O, S, and H2; R4 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NR2 and halide; R is selected from H, substituted or unsubstituted aryl, and, substituted or unsubstituted 1 to 20 carbon linear, branched, or cyclic, saturated or unsaturated alkyl in which alkyl carbon atoms are replaced by 0 to 10 oxygen, 0 to 10 sulphur, and 0 to 10 N atoms; and with the proviso that when W is H2, R4 is not H, OH, or unsubstituted phenyl. The ceratamines disclosed are antimitotic heterocyclic alkaloids which may be isolated from marine invertebrates.
Patent NZ-548470-A (NZ)
Title: 6-amino-5-cyano-pyrimidine-4-ones used for improving perception, power of concentration, learning efficiency, and/or memory power
Inventor: HENDRIX MARTIN
IPC: A61K31/513
Filed: 2004-12-31
Abstract: The disclosure relates to the use of cyanopyrimidinones for producing medicaments used for the treatment of impairment of perception, concentration, learning and/or memory where the impairment is a consequence of Alzheimer's disease. These medicaments are also suitable for improving perception, power of concentration, learning efficiency, and/or memory capacity. Also described are methods for the production of certain cyanopyrimidinones that are suitable for producing these medicaments.
Patent NZ-548689-A (NZ)
Title: Antiparasitic composition containing an organic amine salt of closantel
Inventor: ALBRIGHT ROBERT BRUCE
IPC: A61K31/7048
Filed: 2005-01-28
Abstract: Disclosed is an antiparasitic pour-on composition which comprises: an alkanolamine salt of closantel in an amount of about 5% w/v to 60% w/v, wherein the alkanolamine salt has 2 to 10 carbon atoms; a macrocyclic lactone in an amount of about 0.1% w/v to 5% w/v, wherein the macrocyclic lactone is selected fro the group consisting of moxidectin, abamectin, doramectin, eprinomectin and ivermectin; and a pharmaceutically acceptable carrier.
Patent NZ-552548-A (NZ)
Title: An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
Inventor: CHAUDRY IMTIAZ
IPC: A61P11/00
Filed: 2002-10-18
Abstract: Disclosed is a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). The solution is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD and is free of antimicrobial preservatives, such as benzalkonium chloride. In one embodiment the solution comprises from 0.60 mg to 5.0 mg of albuterol and from 0.01 mg to 1.0 mg of ipratropium bromide.
Patent NZ-552571-A (NZ)
Title: Packaging and method for solid dose administration of an electronic identification chip and medicaments to an animal
Inventor: HANSEN RICHARD D
IPC: A61M37/00
Filed: 2005-07-12
Abstract: A method of inoculating non-human animals with an electronic identification microchip and at least one biologically active pellet comprising providing an implant apparatus 12 for implanting the chip and the pellet in an animal which can be operably coupled to a dosing magazine 22, the dosing magazine 22 comprising a series of loaded dosing pellet columns, each column loaded with a microchip having a convex surface which matingly abuts against a concave surface of a biologically active dosing pellet, arranged so that the chip is inoculated first, the pellet being coded to represent a particular medicament, and thereafter, implanting the chip and dosing pellet combination in an animal to be inoculated with a single injection.
Patent NZ-553656-A (NZ)
Title: Injectable composition for animals comprising trace elements and other components
Inventor: LAURIE ROBERT NAYLOR
IPC: A61K33/24
Filed: 2005-09-07
Abstract: The disclosure relates to an injectable trace element solution, which includes (a) 2.5 û 10 mg/ml selenium, (b) 20 û 50 mg/ml zinc, (c) 5 û 15 mg/ml manganese, and (d) at least one component selected from the group consisting of a vitamin, a vaccine, a growth stimulant of the group including zeranol, estradiol, testosterone, progesterone and/or trenbolone acetate, a dewormer of the group including macrocyclic lactones, leramizoles, benzimidazoles and/or salicylanilides, iron dextran, and an antibiotic; (e) with at least one of the metals provided in the form of an EDTA complex and the total metal concentration being at least 60 mg/ml, (f) the EDTA complex obtained by means of at least one compound selected from the group comprising sodium EDTA, sodium hydroxide EDTA acid and potassium EDTA, (g) and the solution being prepared in a continuous batch process.
Patent NZ-555076-A (NZ)
Title: Antibiotic combinations for providing total solution to the treatment of infections
Inventor: CHAUDHARY MANU
IPC: A61K31/7036
Filed: 2005-12-16
Abstract: The disclosure relates to a new pharmaceutical composition comprising: Two different antibiotics and a stabilizing agent suitable for parenteral injection as antimicrobial fixed dose combination therapy for mammals, in dry powder form ready after reconstitution with a suitable solvent for injection, wherein: (a) a first of the antibiotics is a protein synthesis inhibiting antibiotic, selected from a group of aminoglycoside consisting of netilmicin, kanamycin, gentamycin, streptomycin, amikacin, and tobramycin. (b) a second of the antibiotics is not a protein synthesis inhibiting antibiotic and is selected from a group of beta lactam cephalosporin consisting of cefepime, ceftazidime, cefotaxime, cefuroxime, cefaclor, and cetriaxone, (c) the stabilizing agent comprising L- arginine, the first and second antibiotics being present in a weight ratio of 1:5 to 5:1. Also disclosed is a process to prepare the composition. The present disclosure additionally provides a therapy for control of multiresistant P. aeruginosa, or Acinetobacter spp. and / or methicillin - resistant S. aureus, and is useful for intramuscular or intravenous administration as antibiotics for hospitalized patients with acute or serious infections. The pharmaceutical compositions described here have better efficacy and safety of cefepime plus amikacin combination.
Patent NZ-565060-A (NZ)
Title: Method of producing organotypic cell cultures
Inventor: STOPPINI LUC
IPC: C12M3/04
Filed: 2006-06-15
Abstract: Provided is an in vitro method of producing an organotypic culture, the method comprising culturing (i) dissociated cells from an organ or (ii) cells which are explants or microexplants, on a porous membrane wherein the contralateral surface of the membrane to the cells is supplied with liquid medium and the cells are compacted on the membrane to achieve greater than 5% close packing by capillarity exerted by the liquid medium. The organ cells can be from mammalian cells, including human cells.
Patent NZ-566680-A (NZ)
Title: Method of business valuation and data processing system
Inventor: TOMBS DAVE
IPC: G06Q40/00
Filed: 2008-03-13
Abstract: A data processing system for valuing a business is provided. The system includes: (a) processing means for processing data; (b) storage means for storing data; (c) data entry means to enter into the processing means, data related to the financial performance of a business to be valued, including at least an income component, and an expense component, and value optimisation factors that determine business value in the light of the business background and the relevant industry of the business to be valued; (d) the processing means establishing a business capitalisation rate (BCR) appropriate for the business and industry of the business to be valued based on the value optimisation factors and the data related to the financial performance of a business to be valued; (e) the processing means calculating a weighted average notional earning before interest and tax (WANEBIT) based on historical financial records contained in the business background of the business to be valued; and (f) the processing means calculating the net business value using the WANEBIT and the BCR; and (g) the processing means checking that the business capitalisation rate (BCR) established is viable, including the sub-steps of: (i) calculating a peak notional business value ratio (PNBVR) of net business value to total income for an appropriate historical period; (ii) calculating WANEBIT as a percentage of total income for the appropriate historical period; (iii) calculating the business capitalisation rate as a ratio of PNBVR to WANEBIT as a percentage of total income; and (iv) comparing the business capitalisation rate to industry levels for reasonableness.
Patent NZ-567569-A (NZ)
Title: A method of producing perforated retroreflective trim
Inventor: BRENNAN CHRISTOPHER JOHN
IPC: D04H13/00
Filed: 2006-06-02
Abstract: Perforated retroreflective fabric, trim or tape that comprises a substrate (30) having a first and second sides and a plurality of openings (39) extending between the sides, providing a backing (50) on the first side of the substrate, providing a retroreflective layer (40) on the second side of the substrate, adhering the retroreflective layer to the second side and to the backing through the openings and removing the backing from the first side to strip away the retroreflective layer adhered to the backing through the openings in the substrate.
Patent NZ-572268-A (NZ)
Title: Activating agent for peroxisome proliferator activated receptor delta (ppar)
Inventor: SAKUMA SHOGO
IPC: A61P17/14
Filed: 2007-04-18
Abstract: A compound represented by the general formula (I) and a salt thereof which is used as an activating agent for peroxisome proliferator activated receptor (PPAR) delta is disclosed, wherein the variables are as defined in the specification. These compounds of formula (I) are suitable treating a disease mediated by peroxisome proliferator activated receptor delta is hyperlipidemia, dyslipidemia, hyperchlolesterolemia, hypertriglyceridemia, HDL hypocholesterolemia, LDL hypercholesterolemia and/or HLD noncholesterolemia, VLDL hyperproteinemia, dyslipoproteinemia, apolipoprotein A-I hypoproteinemia, atherosclerosis, disease of arterial sclerosis, disease of cardiovascular systems, cerebrovascular disease, peripheral circulatory disease, metabolic syndrome, syndrome X, obesity including internal-organs fat type, diabetes, hyperglycemia, insulin resistance, impaired glucose tolerance, hyperinsulinism, diabetic complication, cardiac insufficiency, cardiac infarction, cardiomyopathy, hypertension, fatty liver, non-alcoholic fatty hepatitis, thrombus, Alzheimer disease, neurodegenerative disease, demyelinating disease, multiple sclerosis, adrenal leukodystrophy, dermatitis, psoriasis, acne, skin aging, trichosis, inflammation, arthritis, asthma, hypersensitive intestine syndrome, ulcerative colitis, Crohn's disease, pancreatitis, or cancer including colon cancer, large intestine cancer, skin cancer, cancer of the breast, carcinoma of the prostate, ovary cancer, or lung cancer.
Patent NZ-573588-A (NZ)
Title: Treatment of edible crops using bcdmh
Inventor: BLISS WILLIAM
IPC: A01N43/50
Filed: 2007-05-18
Abstract: Disclosed is an anti-pathogen concentrate which is produced by adding about 35 parts of bromo-chlorodimethyl hydantoin (BCDMH) and about 1 part silica drier to about 100 parts diacetone alcohol. Further disclosed is a method for the removal of pathogens from crops being grown and intended for human consumption comprising application to a crop, prior to harvest, of irrigation water which contains an anti-pathogen concentrate produced by adding bromo-chlorodimethyl hydantoin (BCDMH) and silica drier to a solvent whose residue is non-toxic and is selected from the group consisting of glycol alcohols, glycol ethers and diacetone alcohol, wherein the BCDMH is used as 5 to 100 ppm as chlorine.